Clinical trial · Observational
A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur
Supplemental Data for the Juvenile Idiopathic Arthritis FDA Written Request
NCT03769558CI-TRIAL-00044153completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will determine the incidences of infections and malignancies among JIA patients treated with abatacept
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Juvenile Idiopathic Arthritis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-Interventional | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- JIA patients prescribed abatacept
- interventionNames
- Other: Non-Interventional
Primary outcomes (1)
- measure
- Incidence of infections
- timeFrame
- 110 months
Secondary outcomes (1)
- measure
- Incidence of malignancies
- timeFrame
- 110 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Months
Show eligibility criteria text
Inclusion Criteria: * Two diagnoses of JIA (ICD-9 code 714.3x) within 90 days * Age less than 18 years at the time of second of the two diagnoses * Index date is the date of initiating treatment with abatacept Exclusion Criteria: * Greater than or equal to 18 years of age
References
Publications (0)
Data not yet available
No reference posted for this study.